There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avidity Biosciences (RNA – Research Report), Caribou Biosciences (CRBU – Research Report) and ACADIA Pharmaceuticals (ACAD – Research Report) with bullish sentiments.
Avidity Biosciences (RNA)
Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Avidity Biosciences on December 13. The company’s shares closed last Thursday at $8.03, close to its 52-week low of $4.83.
According to TipRanks.com, Schwartz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avidity Biosciences with a $36.00 average price target, implying a 350.6% upside from current levels. In a report issued on November 28, Needham also maintained a Buy rating on the stock with a $35.00 price target.
See the top stocks recommended by analysts >>
Caribou Biosciences (CRBU)
Leerink Partners analyst Mani Foroohar maintained a Buy rating on Caribou Biosciences on December 13 and set a price target of $24.00. The company’s shares closed last Thursday at $6.17.
According to TipRanks.com, Foroohar is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Caribou Biosciences with a $21.80 average price target, representing a 270.1% upside. In a report issued on December 4, Citi also assigned a Buy rating to the stock with a $30.00 price target.
ACADIA Pharmaceuticals (ACAD)
Leerink Partners analyst Marc Goodman maintained a Buy rating on ACADIA Pharmaceuticals on December 13. The company’s shares closed last Thursday at $28.06.
According to TipRanks.com, Goodman is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $33.93 average price target, implying a 24.6% upside from current levels. In a report issued on December 13, Citi also initiated coverage with a Buy rating on the stock with a $38.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RNA:
- Avidity Biosciences announces data from Phase 1/2 EXPLORE44 clinical trial
- Biotech Alert: Searches spiking for these stocks today
- Bristol-Myers (NYSE:BMY) Expands Collaboration with Avidity Bio in $2.3B Deal
- Avidity Biosciences expands cardiovascular collaboration with Bristol Myers
- Avidity Biosciences reports Q3 EPS (71c), consensus (77c)
